Article Text

PDF
Inhaled insulins
  1. Sujoy Ghosh,
  2. Andrew Collier
  1. Ayr Hospital, Ayr, Ayrshire, UK
  1. Correspondence to:
 Dr Andrew Collier
 Ayr Hospital, Dalmellington Road, Ayr, Ayrshire KA6 6DX, UK; andrew.collier{at}aaaht.scot.nhs.uk

Abstract

As a result of knowledge gained from the management of asthma with inhalers and nebulisers, pulmonary delivery devices for insulin have been developed. Particle size of the aerosol particularly influences drug delivery. Although several pharmaceutical companies are developing different systems, Pfizer have launched the first inhaled insulin (Exubera). Clinical trials have taken place in patients with both type 1 and type 2 diabetes, but have shown similar glucose control as subcutaneous insulin delivery. However, patient satisfaction does seem to be increased in patients taking inhaled insulins. Further studies are needed to investigate compliance, side-effect profiles, quality of life, long-term glycaemia control and cost effectiveness.

  • FEV1, forced expiratory volume in 1 s
  • HbA1c, haemoglobulin A 1c
  • NICE, National Institute of Clinical Excellence
  • inhaled insulin

Statistics from Altmetric.com

Footnotes

  • Competing interests: None.

  • Sources and selection criteria: We reviewed literature listed in Pubmed under the heading “inhaled insulin” from 1966 until June 2006. We obtained further articles from the references cited in the initial literature review.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.